The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Results from the Phase III VEGA-3 trial show that a significantly higher number of patients with presbyopia who received ...

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Former Philadelphia Eagles quarterback Rodney Peete joined Sumitomo Pharma America’s Time to Go campaign. 1 The promotional ...

Results from the Phase III Vivacity-MG3 trial show that Imaavy provides more consistent disease control than other approved ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

Gamifant marks the first-ever FDA-approved treatment for both adult and pediatric patients with hemophagocytic ...